STAT Plus: Biomarin to seek approval for hemophilia gene therapy, but durability questions persist
ADOBE
The company said that an experimental gene therapy targeting hemophilia A continued to help patients produce a protein enabling blood to clot.
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario